BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a United States-based biotechnology company, has dosed its final participant in the phase three pivotal trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS), it was reported on Thursday.
The company enrolled around 200 participants in the trial and randomised 1:1 to receive three doses of MSC-NTF cells or placebo, administered in a period of four months. The trial is being conducted at six centres of excellence, University of California, Irvine; Cedars-Sinai Medical Center; California Pacific Medical Center; Massachusetts General Hospital; University of Massachusetts Medical School and Mayo Clinic.
The firm is likely to reveal top-line data from the trial in the fourth quarter of 2020.
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study
SparX Biopharmaceutical doses first subject with SPX-303 injection
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Gabather collaborates with Denmark's Centre for Neuropsychiatric Schizophrenia Research
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
4basebio supplies opDNA DNA products to Tier 1 Pharma client
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories